23.34
-0.46 (-1.93%)
| Previous Close | 23.80 |
| Open | 23.40 |
| Volume | 278,159 |
| Avg. Volume (3M) | 311,221 |
| Market Cap | 1,045,029,632 |
| Price / Sales | 53.98 |
| Price / Book | 3.07 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -11,831.05% |
| Diluted EPS (TTM) | -1.78 |
| Quarterly Revenue Growth (YOY) | -30.90% |
| Total Debt/Equity (MRQ) | 6.25% |
| Current Ratio (MRQ) | 32.19 |
| Operating Cash Flow (TTM) | -74.10 M |
| Levered Free Cash Flow (TTM) | -25.69 M |
| Return on Assets (TTM) | -17.20% |
| Return on Equity (TTM) | -30.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Septerna, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.13 |
|
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 2.64% |
| % Held by Institutions | 105.46% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 43.00 (Jones Trading, 84.23%) | Buy |
| Median | 35.00 (49.96%) | |
| Low | 28.00 (Wells Fargo, 19.97%) | Buy |
| Average | 35.60 (52.53%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 27.06 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Jan 2026 | 35.00 (49.96%) | Buy | 27.03 |
| Jones Trading | 23 Dec 2025 | 43.00 (84.23%) | Buy | 28.23 |
| Raymond James | 19 Dec 2025 | 38.00 (62.81%) | Buy | 29.58 |
| Truist Securities | 15 Dec 2025 | 34.00 (45.67%) | Buy | 27.18 |
| Wells Fargo | 14 Nov 2025 | 28.00 (19.97%) | Buy | 23.27 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Jan 2026 | Announcement | Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer |
| 17 Dec 2025 | Announcement | Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 25 Nov 2025 | Announcement | Septerna to Participate in 8th Annual Evercore Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |